SARS-CoV-2 Vaccine Alpha and Delta Variant Breakthrough Infections Are Rare and Mild but Can Happen Relatively Early after Vaccination
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SARS-CoV-2 Vaccine Alpha and Delta Variant Breakthrough Infections Are Rare and Mild but Can Happen Relatively Early after Vaccination
Authors
Keywords
-
Journal
Microorganisms
Volume 10, Issue 5, Pages 857
Publisher
MDPI AG
Online
2022-04-21
DOI
10.3390/microorganisms10050857
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern
- (2022) Paul R. Wratil et al. NATURE MEDICINE
- Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals
- (2022) Thomas Lechmere et al. mBio
- Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19
- (2021) Kathryn E. Stephenson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
- (2021) Noa Dagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data
- (2021) Gabriel Chodick et al. CLINICAL INFECTIOUS DISEASES
- Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
- (2021) Eric J Haas et al. LANCET
- Vaccine Breakthrough Infections with SARS-CoV-2 Variants
- (2021) Ezgi Hacisuleyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Covid-19: Stronger warnings are needed to curb socialising after vaccination, say doctors and behavioural scientists
- (2021) Michael Day BMJ-British Medical Journal
- SARS-CoV-2 outbreak in a tri-national urban area is dominated by a B.1 lineage variant linked to a mass gathering event
- (2021) Madlen Stange et al. PLoS Pathogens
- BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel
- (2021) Tal Brosh-Nissimov et al. CLINICAL MICROBIOLOGY AND INFECTION
- Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study
- (2021) Michela Antonelli et al. LANCET INFECTIOUS DISEASES
- Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
- (2021) Delphine Planas et al. NATURE
- Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings
- (2021) Mark G. Thompson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
- (2021) Mark G. Thompson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
- (2021) Moriah Bergwerk et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
- (2021) Stephen J. Thomas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hybrid immunity
- (2021) Shane Crotty SCIENCE
- Clinical effectiveness of COVID‐19 vaccination in solid organ transplant recipients
- (2021) Saima Aslam et al. Transplant Infectious Disease
- Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients
- (2021) Caroline X. Qin et al. TRANSPLANTATION
- Understanding Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination
- (2021) Michael Klompas JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity
- (2021) Mark W. Tenforde et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- External Quality Assessment of SARS-CoV-2 Sequencing: an ESGMD-SSM Pilot Trial across 15 European Laboratories
- (2021) Fanny Wegner et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
- (2021) Noam Barda et al. LANCET
- Protective immunity after recovery from SARS-CoV-2 infection
- (2021) Noah Kojima et al. LANCET INFECTIOUS DISEASES
- The emergence, genomic diversity and global spread of SARS-CoV-2
- (2021) Juan Li et al. NATURE
- Metabolic disorders, COVID-19 and vaccine-breakthrough infections
- (2021) Norbert Stefan Nature Reviews Endocrinology
- Mechanisms of SARS-CoV-2 entry into cells
- (2021) Cody B. Jackson et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
- (2021) Hiam Chemaitelly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants
- (2021) Matthew McCallum et al. SCIENCE
- Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine
- (2021) Barak Mizrahi et al. Nature Communications
- Omicron variant and booster COVID-19 vaccines
- (2021) Talha Khan Burki Lancet Respiratory Medicine
- Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era
- (2021) Stephen Y Wang et al. Lancet Microbe
- The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study
- (2021) Jeffrey P Townsend et al. Lancet Microbe
- Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
- (2020) Jun Lan et al. NATURE
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started